Episoder

  • The European Health Data Space is around the corner. The legislation is confirmed. How do we get to the next steps? Today you will hear a discussion with Eric Sutherland, Senior Health Economist and Digital Health Lead at OECD, who worked on the pan-Canadian health data strategy before his current role. We discussed the upcoming implementation of the European Health Data Space, what needs to happen next, how do we involve the public, encourage trust in data sharing, and also build capacity for digital health implementation. We are moving into the era of new required data professionals, not just data analysts, but also data controllers, data stewards and more. 

    www.facesofdigitalhealth.com
    Newsletter: https://fodh.substack.com/

    Show notes:
    [00:02:00] - Eric Sutherland's background and transition from Canada to OECD
    [00:04:00] - Challenges and solutions in Canadian health data strategy, emphasizing the need for data stewardship and public engagement
    [00:06:00] - Importance of data interoperability and policy compatibility across regions
    [00:08:00] - Goals of Canadian health data strategy and its impact, focusing on improving healthcare delivery through better data utilization.
    [00:10:00] - Governance and collective impact in Canadian healthcare
    [00:12:00] - European health data space and public engagement
    [00:14:00] - Opt-out provisions and public interest in European health data space
    [00:16:00] - Setting standards and policy compatibility in Europe
    [00:18:00] - Learning from historical approaches in healthcare data strategies
    [00:20:00] - Digital health literacy and public engagement
    [00:22:00] - Simplifying communication in digital health
    [00:24:00] - Role of patient leaders and public deliberation in health policy
    [00:26:00] - Public expectations on health data usage
    [00:28:00] - Economics of digital health and ROI
    [00:30:00] - Utilizing health data for policy and research
    [00:32:00] - Interoperability and investment in digital health infrastructure
    [00:34:00] - Shifting towards a prevention-based health system
    [00:36:00] - Workforce and capacity building in digital health
    [00:38:00] - Automation and the future of health workforce

  • AI and predictive modeling to understand an individual’s immune system function and predict treatment response are still in very early stages. We dream about precision medicine and getting every answer we can for ourselves when we get sick. However, if we look at genomics, only about 20 percent of human coding genes are well-studied. The remaining 80 percent (about 16,000 genes, along with the proteins they make) are largely a mystery. 
    In this episode, you will hear more about the field of immuno-oncology, understand the correlation between tumor development and immune system response, and trends in cancer detection and prevention, especially liquid biopsies - tests for detecting tumors in blood samples. 
    Speaker: Brian Hashemi - Executive Chairman and CEO of Novigenix - a Swiss-based biotech company using AI and RNA sequence analysis to capture the cancer immunity cycle during the multi-stage disease progression and response to therapy.
    www.facesofdigitalhealth.com
    https://fodh.substack.com/

    Show notes:
    [00:02:00] The use of AI and RNA sequence analysis in capturing the cancer immunity cycle and disease progression
    [00:04:00] Biotech in Switzerland
    [00:06:00] The impact of Swiss biotech capabilities on global healthcare and the specific advancements made by Swiss companies in the field.
    [00:08:00] Predictions and hopes for the future of healthcare technology, especially in the realms of cancer detection and treatment.
    [00:10:00] Challenges and opportunities in biotech, and the role of AI in advancing healthcare.
    [00:12:00] Challenges in Colorectal Cancer Screening
    [00:14:00] The Impact of Liquid Biopsy on Clinical Trials and Drug Development
    [00:16:00] Market Adoption and Patient Accessibility to Liquid Biopsy Tests
    [00:18:00] The Future of Liquid Biopsy and Precision Medicine
    [00:20:00] Real-world Application and Impact of Novel Biomarkers
    [00:22:00] Expanding the Reach of Novel Diagnostics Beyond Switzerland
    [00:24:00] Partnerships and Collaborations to Accelerate Adoption

  • The Gulf Cooperation Council (GCC) brings together six Arab countries – Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates 
    When one reads about the GCC countries, there’s nothing but the impression of prosperity: high investments, determination, and enthusiasm in tech-supported healthcare. 
    The spending on healthcare by the GCC governments is on an astronomical rise. From a regionwide US$2.4 billion in 2016, it rose to more than US$30 billion in 2021 and is projected to surpass US$104 billion this year, according to a report from the UAE Ministry of Economy. 
    In this episode, Pilar Fernandez Hermida International Go-to-Market expert with 20+ years of experience launching sales & partner ecosystem strategies, talks about the potential of the Middle East and MENA region for healthtech companies, the culture in the Middle East, how to interpret different style of communication here, what are the common entrepreneurial misconceptions, and where to find opportunities. Pilar says that the entrepreneurial spirit here is 10-times as strong as in the US, and that biotech and drug development are the next thing to watch for in the region.


    www.facesofdigitalhealth.com
    Newsletter: https://fodh.substack.com/
    Show notes:

    [00:02:00] Pilar Fernandez Hermida, an expert in healthcare market strategies, shares insights from Abu Dhabi.

    [00:04:00] Analysis of the healthcare infrastructure development in GCC post-pandemic.

    [00:08:00] The role of expats in the Middle East's healthcare transformation.

    [00:10:00] Public-private partnerships as key opportunities.

    [00:12:00] Cultural considerations for startups in the GCC.

    [00:14:00] Misconceptions about the Middle Eastern healthcare market.

    [00:18:00] Building long-term relationships in business.

    [00:20:00] Navigating diverse cultural communication in healthcare.

    [00:24:00] Comparing the entrepreneurial spirit in the Middle East with the U.S. and Europe.

    [00:28:00] Strategic advice for healthcare entrepreneurs targeting the GCC.

    [00:30:00] Importance of understanding regulations and digital maturity in MENA.

    [00:32:00] Future potential in biotech and digital health in the GCC.

    [00:36:00] The convergence of digital health and biotech.

  • In the last few years, we've witnessed a whirlwind of developments in the world of Digital Therapeutics (DTx) - from FDA approvals sparking optimism for the industry, to the establishment of regulatory frameworks in countries like Germany, France, and Belgium.
    However, in 2023, the industry faced a stark reality check, marked by the fall of some key players and healthcare systems' hesitancy towards embracing and financing these innovations. This turbulence has reshaped strategies and raised critical questions about the future of DTx.
    🔍 In this episode learn more about:
    📊 The current state of the DTx industry in 2024,
    🗣️ Key debates of digital therapies industry players,
    🌐 Advocacy efforts pushing the boundaries for global adoption,
    🚀 Strategies to accelerate the integration of digital therapies worldwide.

    Newsletter: fodh.substack.com
    Website: www.facesofdigitalhealth.com

  • Patient-reported outcomes (PROs) have become increasingly integral in healthcare for assessing the effectiveness of treatments from the patient's perspective. It sounds like a reasonable step in improving clinical research and care provision, but gathering data can be more difficult then you may think. It isn't easy to get to marginalized communities. There are language barriers in collecting data. There are cultural aspects that impact responses. So, how can you design useful electronic solutions for patient-reported outcomes? Hear from Mustafa Ali Syed, Researcher at the Manchester Academic Health Science Centre, The University of Manchester, and Ben James, Co-founder/Chief Design Officer at uMotif - ePRO, an engagement platform designed to power clinical and real-world research. Both are co-authors of a recently published paper titled Exploring the Cross-cultural Acceptability of Digital Tools for Pain Self-reporting.

    www.facesofdigitalhealth.com
    Newsletter: https://fodh.substack.com/

    Show notes:
    00:00:00 Why Do PROs Matter?
    00:04:00 Evolution of Data Collection
    00:06:00 Importance of Diversity in Clinical Trials
    00:08:00 Ethnicity, Culture, and Pain Perception
    00:12:00 The Role of Technology in PROs
    00:14:00 Designing Inclusive Digital Solutions
    00:20:00 Challenges in Engaging Targeted Populations
    00:22:00 Language and Communication Barriers
    00:26:00 The Future of PRO Research

  • Did you know that Belgium has had an idea for classifying and validating digital therapeutics since 2018? A clear framework was formed with all main stakeholders involved - from health insurance to the industry. So why are we not hearing more about DTx in Belgium? In this discussion you will hear from Dr. Steven Vandeput - he is the Advisor for Digital MedTech and Services & Technologies Home Assistance in Belgium; he is managing the mHealthBelgium portal and, since 2019, has been a representative for beMedTech, the sector federation that represents the industry of medical technologies in Belgium. Website: www.facesofdigitalhealth.comNewsletter: https://fodh.substack.com/Show notes: 00:00 - Introduction01:45 - Digital Therapeutics in Belgium03:50 - Belgium's Healthcare Framework Development06:00 - The Validation Pyramid and Reimbursement System08:00 - Fate of Pilot Projects and Their Impact10:00 - Utilization of mHealth Belgium Portal12:00 - Challenges in Reimbursement and Financing14:00 - Prospects for Digital Therapeutic Companies16:00 - Belgium's Approach to Financing Digital Health18:00 - Anticipations for the Digital Health Field20:00 - The Evolving European Frameworks22:00 - Impact of Political Decisions and Healthcare System Integration24:00 - The Future of mHealth Belgium Platform

  • The field of oncology treatments is advancing very fast with innovative therapies and approaches on the market every day. It can get very tricky to support these therapies from an IT perspective, which is what you will hear more about in this discussion. I spoke with Anish Patankar, SVP and GM of Elekta’s Oncology Software Solutions, and we discusses:

    How to go about the US hospital market, 

    Development in software for oncology treatments,

    Challenges in scaling healthcare IT software across markets. 


    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

    Show notes:
    [00:00:00] Introduction to Elekta
    [00:02:00] Elekta's Global Presence
    [00:04:00] US Market Focus
    [00:06:00] Growth in Developing Countries
    [00:08:00] Segmentation and Technology Adoption in the US
    [00:10:00] Untapped Needs and Opportunities in the US
    [00:12:00] Elekta's Use of AI
    [00:14:00] Patient Feedback and Clinical Decision Making
    [00:18:00] Navigating Legacy Software in Healthcare IT
    [00:20:00] Modernization and Customer Satisfaction
    [00:22:00] Global Standardization and Regulation Challenges
    [00:24:00] Interoperability and Open Ecosystem
    [00:26:00] Future of Oncology Market Development: the interplay between medications and radiation, and the potential of theranostics.
    [00:28:00] Exciting Technologies in Healthcare Beyond Oncology: personalized healthcare, digital twins
    [00:30:00] Cautions for the Future: The critical debate on the balance between innovation speed and safety, particularly with generative AI.

  • In 2023, Insilico Medicine—a biotech company developing medications with a heavy reliance on AI—used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China, with some results expected in early 2025.
    Biotech is one of the fields that has been using generative AI for years, even before ChatGPT brought the technology to public view.
    Latest technology is essential in drug development. However, the convergence of digital health and pharma seems less clear. Digital health apps started gaining popularity around 2015, and at that time, it seemed all pharma companies were trying to figure out what they could gain from apps, so they financed accelerators and incubators one after the other.
    We've seen many ideas about how Pharma should or could use digital health.
    In the last few years, there have been many notorious cases when partnerships failed—a seemingly unicorn, Proteus, which designed digital sensors-equipped pills, went bankrupt in 2019 after Otsuka Pharmaceuticals pulled out of a funding round. Pear Therapeutics, the guiding star in the DTx space and the leader in FDA-cleared prescription digital therapeutics, partnered with Novartis, but in the end, the company filed for bankruptcy in 2023. So where is Pharma in relation to digital health and digital therapeutics? In this episode, Amir Lahav shares his thoughts about the impact of AI on biotech, the state of decentralized clinical trials, and the potential of technology for improved drug development, clinical trials, and patient responses.

    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

    Show notes:
    [00:02:00] The Convergence of Digital Health and Pharma

    Discussion on the role of digital health apps in pharmaceuticals.

    The rise and fall of pharma and tech company partnerships, with examples like Proteus and Peer Therapeutics.

    [00:06:00] AI Trends in Biotech and Pharma
    [00:08:00] Enhancing Clinical Trials with AI and continuous patient monitoring
    [00:10:00] The Importance of Data in Clinical Trials
    [00:12:00] The Reality of Oncology Trials and Endpoints
    [00:14:00] Quality of Life in Medicine as the Endpoint
    [00:16:00] The Rise of Decentralized Clinical Trials
    [00:18:00] Pharma's Evolving Digital Health Strategies
    [00:22:00] Impact on Digital Health Industry
    [00:24:00] Collaboration and Sharing Knowledge in the Pharma Industry
    [00:26:00] The need for long-term investment and strategic piloting of digital health solutions
    [00:28:00] What Inspires in Pharma and Biotech in Personalized Treatments
    [00:30:00] The State of Precision Medicine and Targeted Therapies
    [00:34:00] The Role of Pharmacogenomics
    [00:36:00] Anticipations for 2024 and Beyond

  • HLTH (https://hlth.com/) is an event where you will see a literal forest on one of the stages, be able to take a selfie with a unicorn mascot, and get perks like hlth branded pink nail polist on your entrance. In the last few years, HLTH has become the most flashy, visible and must-go digital health event in the US.
    In this episode, Richard Scarfo, president of HLTH, talks about HLTH's approach to making events memorable, why HLTH is taking experience economy as a guiding principle in the investment in the scene at HLTH. You will also hear networking tips, and why HLTH is coming to Europe in June 2024. 

    HLTH Europe (17-20 June 2024): https://europe.hlth.com/

    www.facesofdigitalhealth.com
    Newsletter: https://fodh.substack.com/

  • Migraine is 3 times more common in women than in men. 
    2/3 of patients with Alzheimer’s disease.
    Gender differences are real and they matter. 
    The Women's Brain Project (WBP) is a Swiss-based international non-profit organization founded in 2016. It comprises a diverse team of academic and social scientists, medical doctors, engineers, patients, caregivers, artists, and AI experts. The WBP focuses on understanding sex and gender differences in brain and mental diseases to pave the way for precision medicine. This involves tailoring medical treatment to the individual characteristics of each patient, including factors like sex, gender, genomic and proteomics, microbiome, ethnicity, and socio-economic status​​.
    In this episode Antonella Santuccione Chadha, medical doctor and CEO of Women’s brain project and Anna De, Head of Stakeholder Engagement at Women's Brain Project explain: where are we with data about women’s health specifics, what is driving research in women’s health, what is the negative health and societal impact on women because of their predominant role in caregiving.
    Show notes:
    [00:03:01] Antonella Discusses Women's Brain Project:

    The gaps in medicine for not considering sex and gender.

    The transformation from an association to a foundation.

    The need for commitment and support for evidence generation.

    [00:05:20] Underrepresentation of Women in Research:

    Antonella explains historical exclusion of women and the current need for inclusion.

    Addressing biases and the importance of female leadership in medicine.

    [00:08:23] Evaluating Existing and New Treatments:
    The role of real-world data in addressing the gap in gender responses to treatments.
    [00:11:27] Key Findings and Successes:
    Antonella passes the conversation to Anna to discuss policy successes.
    [00:11:59] Anna Discusses Policy Impact:

    How Women's Brain Project informs global policy.

    Collaboration with large organizations and efforts to influence policy.

    [00:16:01] Migraine Research and Campaigns:
    Details on the migraine awareness campaign and insights on how it impacts women specifically.
    [00:19:30] Antonella on Scientific Evidence:

    The role of female hormones in migraines and other diseases.

    The importance of translating science into political measures.

    [00:20:38] Alzheimer's Disease in Women:
    Discussion on why two-thirds of Alzheimer's patients are women and associated factors.
    [00:26:00] Relationship Between Research and Medical Practice:

    Antonella shares her experiences as a clinician and the realization of gender disparities in her patients.

    The importance of educating healthcare professionals on sex and gender differences.

    [00:29:03] Anna Adds to the Discussion:

    The need to consider both sex and gender differences in healthcare.

    The societal impact of caregiver burden on women.

    [00:33:34] Identifying Questions and Approaches for Research:
    The conversation turns to the complexities of starting research with the right questions and data.
    [00:37:18] Key Changes Needed to Advance Women's Health:
    Antonella and Anna discuss the three key changes they hope to see: investment in women-driven innovation, prioritizing sex and gender differences in policy agendas, and empowering women with knowledge about their health.
    [00:41:34] Closing Remarks:

    The need for more research and better patient management, especially regarding menopause.

    The call for the younger female generation to lead change.


    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

  • Laboratory tests provide doctors with crucial information for diagnosis, monitoring disease progression, evaluating organ function, assessing risk factors for diseases and more. Laboratory testing can be reassuring, however, it is often deemed unnecessary. In this short episode recorded at HLTH, we’re going to talk about laboratory test optimization. How can it be done without undermining clinical autonomy, what kind of real-time insights can be offered to doctors with tech and more. You will hear from Pam Stahl, President of of Avalon Healthcare Solutions - American Lab Insights Company, that help payers and providers optimize treatments, improve outcomes, and drive down overall cost.

    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

    Show notes:
    [00:02:04] - Introduction to Avalon Health Solutions and their role in generating actionable insights from lab results.
    [00:02:21] - Discussion on the big picture problem in healthcare: the overuse and underuse of lab tests and the drive towards improving clinical decision-making.
    [00:03:25] - Clarification on Avalon's approach to managing unnecessary tests and their non-involvement in claims adjudication.
    [00:03:49] - Explanation of how Avalon provides guidance on appropriate test ordering and interpretation based on evidence-based medicine.
    [00:04:20] - The learning curve for providers in test ordering and the issue of test misuse.
    [00:05:16] - Areas where lab tests are often underutilized, particularly in cancer diagnosis.
    [00:05:45] - The potential of using lab data predictively, with a focus on chronic kidney disease.
    [00:06:20] - How Avalon creates patient profiles and uses predictive analytics to improve healthcare management.
    [00:06:53] - Avalon's ongoing development of predictive models and their impact on healthcare.
    [00:07:36] - The challenge of changing the status quo in lab test utilization and the cost savings involved.
    [00:07:47] - Avalon's growth and the scale of their operations, with a client base of 33 million members.
    [00:08:00] - The role of patient engagement and communication strategies in healthcare management.
    [00:08:41] - The importance of accurate and clear communication channels with patients to avoid confusion.
    [00:09:08] - The rapidly evolving field of genetic testing and Avalon's role in managing the abundance of available tests.
    [00:10:07] - Addressing concerns about over-systemizing lab test ordering and the potential for provider friction.
    [00:11:13] - Feedback from clinicians and Avalon's clinical advisory board on the impact of their services.
    [00:11:55] - The broader implications of cost savings and sustainability in healthcare through better lab test management.
    [00:12:11] - In-depth look at predictive analytics and its application in healthcare outcome improvements.
    [00:13:18] - Strategies for Avalon's customer expansion and managing growth.

  • In this episode, you’re going hear about the German market for digital health startups, the innovation approach at Charite, one of Europe's largest university hospitals, the challenges with digital therapeutics in Germany and beyond. I spoke with Dorothée Marie-Louise Döpfer,
    Deputy Head of Digital Labs and program Manager of the Digital Health Accelerator & Community Building at Charite UMC Berlin. Dorothee also shared her expectations about the impact of AI on European health systems. 

    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

  • ePrescribing has become a norm in the US healthcare system. Now, the expanded role of pharmacists and the integration of non-physician prescribers into the healthcare system signifies a move towards a more accessible healthcare model, potentially alleviating some of the clinicians' burdens.
    Surescripts is the national provider of the ePrescribing infrastructure in the US. In this short discussion, I spoke with Dr. Lynne Nowak, Chief Data and Analytics Officer, and Melanie Marcus, Chief Marketing and Customer Experience Officer at Surescripts, about the importance of ePrescribing on a national level, the changing role of pharmacists, and how it facilitates the redistribution of healthcare provision burdens. 

    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

  • Digital health funding has fallen significantly since 2020. However, funding for Femtech went from 7,6% inside the digital health investments in 2020 to 13,26% in 2022, according to TechCrunch. The awareness about female-specific health-related characteristic has been on the rise for the last several years, which is evident in the growing healthcare innovation space specifically targeting women. In this discussion, you will hear from Marija Butković - founder and CEO of Women of Wearables, a Venture Partner at Simsan Ventures, and an advisor for multiple global organizations in the women's health space. Marija talked about:

    The challenge of providing appropriate care and support to women (for issues like menstruation, menopause, and conditions like endometriosis) without creating a sense of inequality or sidelining men,

    data-driven approaches in addressing women's health issues, 

    trends in women's health for the year 2023, including a broader understanding of fertility issues.


    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

  • Technically, we've never been more connected or had relationships with as many people as we do today, thanks to social networks on the internet. Yet, while these platforms bring convenience, they are also increasing loneliness and reducing face-to-face interactions. However, technology isn't solely a problem; it can facilitate the easier pairing of individuals who wish to assist those lacking a real-world social network. Take Papa, for example, a company that provides social support by pairing older adults and families with trained and vetted companions known as Papa Pals. In this brief episode, you will listen to a discussion with Ellen Rudy, the former Head of Research and Social Impact, whom I met at HLTH 2023. Ellen shares her insights on the causes of solitude and the potential of technology to mitigate loneliness.

    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

  • HLTH is recognized as the United States' number one health innovation event. Its unique and vibrant approach sets it apart from typical industry conferences. Each stage at HLTH is distinctively themed and designed, featuring motifs like the moon, sky, and earth, creating an awe-inspiring experience reminding of of a child's first visit to an amusement park. Beyond the captivating atmosphere, the core attraction of HLTH lies in its substantive content and guests. These include key stakeholders from top tech companies, including pop stars who entered healthcare, or public figures such as Arianna Huffington or Chelsea Clinton. In 2024, HLTH will also be organized in Europe. The event concept will be the same, but the content will be prepared by a European team to touch upon key topics in the European space. While they were enjoying their team building in Ljubljana, Tjasa Zajc sat down with Jody Tropeano, Head of Content at HLTH US and Henry Stoneley, Head of UK and Netherlands. They discussed Jody’s and Henry’s reflections on healthcare in the US, key trends, and challenges.

    Video interview: https://www.youtube.com/watch?v=blT9PIJGfuA
    Newsletter: https://fodh.substack.com/
    www.facesofdigitalhealth.com

  • In patient included or patient centred healthcare approach, patient feedback is key for improved care, and healthcare experience. Pep Health uses a digital platform to collect and analyze patient feedback from various online sources, moving away from traditional, less effective survey methods.
    The platform provides detailed scores and insights, allowing healthcare providers to make targeted improvements in specific areas like access and quality within their facilities. The data and insights generated are influencing healthcare policies and practices, leading to changes in areas such as maternity services and mental health care delivery.
    At HLTH 2023, founder of Pep Health Meghan Leaver shared more insights behind:

    Innovation in the patient feedback gathering,

    What actionable insight healthcare providers can get from PEP insights,

    Impact patient feedback analysis can have on policymaking


    Episode summary: https://www.facesofdigitalhealth.com/blog/why-patient-feedback-is-a-goldmine-for-improvements
    Newsletter: https://fodh.substack.com/

  • Generative AI is making waves in healthcare, with an already visible impact in documentation and potential in drug development, medicine, care, and more.
    With 2023 nearing its end, it's time to reflect on the impact of AI in 2023.
    This episode offers:
    🔍 A recap of AI innovation in healthcare in the past year,
    🔎 What has realistically changed in clinical practice,
    🔍 Where are the practical applications of AI and LLMs in healthcare,
    🔎 How is AI regulated so far and what are the upcoming changes,
    🔍 What can we expect in the upcoming years?

    Speakers:
    👉 Shweta Maniar, Director of Global Healthcare & Life Sciences Industry Strategy at Google,
    👉 Rachel Dunscombe, CEO of openEHR International Foundation,
    👉 Kira Radinsky, CEO & CTO at Diagnostic Robotics,
    👉 Harvey Castro, MD, MBA., Clinician, Healthcare Futurist, Public Speaker

    See the video recording if this live stream: https://www.youtube.com/live/Aul1vm2lUzQ?si=RBS9RG4hHRZRqxBU
    Check out the newsletter for the summary which will be published soon: https://fodh.substack.com/
    www.facesofdigitalhealth.com

  • Women's health refers to a broad range of medical and wellness services specifically tailored to address the unique health concerns of women. Particular focus is on reproductive health, fertility, and menopause. Technology supporting women’s health can go from EHR records, telemedicine services, medical imaging, diagnostic and IVF technology, wearable devices for monitoring health, menstrual cycles, menopause symptoms, robotic surgery in gynecology, and more. 

    This episode focuses on the fertility market with investor Leslie Shrock, author, entrepreneur, and angel investor working at the convergence of health and technology. Leslie Schrock wrote two books: Bumpin’: The Modern Guide to Pregnancy, which mixes the latest clinical research with practical advice for working families and Fertility Rules, published in June 2023, which addresses male and female fertility. In this discussion, Leslie shared her insights into: 
    - key misconceptions and lack of knowledge we have around fertility,
    - how is the market developing, 
    - what technologies she is hoping to see,
    - what investment models seem to be working so far.
    Recap: https://www.facesofdigitalhealth.com/blog/fertility-womenshealth-leslie-schrock
    Newsletter: https://fodh.substack.com/
    Website: www.facesofdigitalhealth.com

  • If you’re still trying to wrap your head around the use of AI in healthcare, this episode will give you an idea about the use of generative AI to create clinical notes during an interaction between a doctor and a patient. Augmedix, a healthcare technology company that delivers ambient medical documentation and data solutions. Their clinician-controlled mobile app uses generative AI to instantaneously create a fully automated draft medical note after each patient visit. I spoke with Manny Krakaris - CEO of Augmedix, about the HOW. How is their data model built, what and what kind of technology do they use in their product? Manny also explains why they’re not covering revenue cycle management or RCM-related codes in their data structuring processes, and what are the biggest challenges in the industry at the moment. 
    The second part of this episode is unrelated to generative AI, and illustrates how existing medical data can be used to create risk prediction tools for medical care. You will hear from Nassib Chamoun, Founder and CEO of the Health Data Analytics Institute, an analytics company that is developing risk modeling methodology to ease clinical decision-making by assigning patients different risk scores based on their medical history. This enables clinicians to design follow-up protocols based on an individual's potential health deterioration. Both discussions were recorded at HLTH.
    Read a longer article about insights related to generative AI from HLTH, which includes an overview of the key player in medical notes generation space: https://fodh.substack.com/p/generative-ai-in-healthcare.
    Episode summary: https://www.facesofdigitalhealth.com/blog/ai-for-medical-note-taking-and-risk-scoring-augmedix-hdai
    Augmedix: https://augmedix.com/
    HDAI: https://www.hda-institute.com/
    Discussion summary:
    More about healthcare data in the US:
    Healthcare data in the US series: https://www.facesofdigitalhealth.com/blog/healthcare-data-series-in-the-us-foundy-epic-komodo?rq=epic%20
    Newsletter: https://fodh.substack.com/
    Website: www.facesofdigitalhealth.com
    Leave a rating or review in iTunes: https://www.facesofdigitalhealth.com/subscribe